Skip to main content

ELVCAP-001-01 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

NCT04383210

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Elevation Oncology

The purpose of this study is to test an experimental drug called seribantumab. Seribantumab is an antibody, which is a type of protein that can locate and bind to substances in the body, including tumor cells. Seribantumab is an antibody that binds to a specific protein found on the surface of cells called HER3 or ErB3. This protein, HER3, is involved in cancer cell growth when activated or triggered by another protein (or 'biomarker') like NRG1. Laboratory studies have shown that Seribantumab blocks NRG1 from binding to and activating the HER3 protein, so that cancer cells do not grow. This study drug, seribantumab, will be given through a small intravenous (IV) catheter into your vein. The study will test if this study drug will prevent your tumor from growing or progressing and increase your voerall survival.

This study is currently enrolling.